Intermittent leukapheresis: an adjunct to low-dose chemotherapy for Sézary syndrome
Affiliations
- PMID: 2563614
Item in Clipboard
Intermittent leukapheresis: an adjunct to low-dose chemotherapy for Sézary syndrome
Acta Derm Venereol.
1989.
Abstract
Eleven patients with Sézary syndrome were treated with intermittent leukapheresis in addition to low-dose chlorambucil and prednisone. The results were as good as or better than those with chemotherapy alone. We believe the combined program with continuous leukapheresis to be optimal therapy but note that intermittent treatment offers some benefit for patients.
Similar articles
-
The treatment of Sézary syndrome.J Am Acad Dermatol. 1984 Jun;10(6):1000-4. doi: 10.1016/s0190-9622(84)80323-0. J Am Acad Dermatol. 1984. PMID: 6736317
-
Exceptionally long disease-free period in a case of Sézary syndrome after combined treatment with leukapheresis and chemotherapy.Haematologica. 1987 Nov-Dec;72(6):541-3. Haematologica. 1987. PMID: 3126113 No abstract available.
-
Leukapheresis in the treatment of Sézary syndrome.J Am Acad Dermatol. 1981 Nov;5(5):544-9. doi: 10.1016/s0190-9622(81)70114-2. J Am Acad Dermatol. 1981. PMID: 7298920
-
Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.Arch Dermatol. 2003 Jun;139(6):771-5. doi: 10.1001/archderm.139.6.771. Arch Dermatol. 2003. PMID: 12810509 Review.
-
Chemotherapy for mycosis fungoides and the Sézary syndrome.Hematol Oncol Clin North Am. 1995 Oct;9(5):1109-16. Hematol Oncol Clin North Am. 1995. PMID: 8522487 Review.